Androgen replacement in women: A commentary

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 6, 1999, Pages 1886-1891

  Davis, Susan ^a  

^a Jean Hailes Foundation for Women's Health   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ESTROGEN; GLUCOCORTICOID; TESTOSTERONE;

ARTICLE; BONE ATROPHY; DRUG INDICATION; FATIGUE; FEMALE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; LIBIDO; OVARY DISEASE; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; WASTING SYNDROME; WELLBEING;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033304561     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.84.6.5802     Document Type: Article

References (49)

1. Andgrogens and postmenopausal women
2. The rationale for physiological testosterone replacement in women
3. The clinical use of androgens in female sexual disorders
4. Twenty-four hour mean plasma testosterone concentration declines with age in normal premenopausal women
5. Sex differences in the 24 hour mean plasma concentrations of dehydroisoandrosterone (DHA) and dehydroisoandrosterone sulfate (DHAS) and the DHA to DHAS ratio in normal adults
6. Evidence for diminished midcycle ovarian androgen production in older reproductive aged women
7. Hormonal dynamics associated with the menopause
8. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women
9. Selective influence of menstrual cycle on perception of stimuli with reproductive significance
10. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
11. Bone loss in young women with karotypically normal spontaneous premature ovarian failure
12. High bone density in hyperandrogenic women: Effect of gonadotropin-releasing hormone agonist alone or in conjunction with estrogen-progestin replacement
13. Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri- and postmenopausal women
14. Associations between low levels of serum estradiol, bone density, and fractures among elderly women: The study of osteoporotic fractures
15. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: A key role for bioavailable estrogen
16. Aromatase expression of human osteoblast-like cells
17. Estradiol and testosterone in specific regions of the human female braIn In different endocrine states
18. Aromatase activity in the rat brain: Hormone regulation and sex differences
19. The true clinical features of postmenopausal oophorectomy and their response to estrogen replacement therapy
20. Oestrogen therapy and the menopausal syndrome
21. Androgen enhances sexual motivation in females: A prespective, crossover study of sex steroid administration in surgical menopause
22. Sexuality in sexagenarian women
23. Estradiol and testosterone implants in the treatment of psychosexual problems in postmenopausal women
24. Effect of combined implants of estradiol and testosterone on libido in postmenopausal women
25. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
26. The climacteric
27. The management of persistent symptoms with estradiol-testosterone implants: Clinical, lipid and hormonal results
28. Skeletal effects of oral estrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women
29. Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms and lipid-lipoprotein profiles in surgical menopause
30. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women
31. Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post menopausal women who have previously received long-term oral oestrogens
32. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
33. Pituitary-adrenal hormones, and testosterone across the menstrual cycle in women with premenstrual syndrome and controls
34. Premenstrual syndromes: Overview from a methodological perspective
35. Should women be treated with testosterone
36. Androgens in rheumatoid arthritis
37. Hormonal and pregnancy relationships to rheumatoid arthritis: Convergent effects with immunological and microvascular systems
38. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis
39. Androgens as adjuvant treatment in postmenopausal female patients with rheumatoid arthritis
40. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months
41. A comparison of esterified estrogens with and without methyltestosterone: Effects on endometrial histology and serum lipoproteins in postmenopausal women
42. Methyltestosterone does not diminish the beneficial effects of estrogen replacement therapy on coronary arter reactivity in cynomolgus monkeys
43. Esterified estrogens with and without methyltesterone decrease arterial LDL metabolism in cynomolgus monkeys
44. Which androgen replacement therapy for women?
45. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women
46. Testosterone, dihydrotestosterone, and oestradiol levels in postmenopausal breast cancer tissues
47. Androgen receptors in breast cancer
48. Medroxy-progesterone acetate therapy in advanced breast cancer: The predictive value of androgen receptor expression